Cellulite Treatment in Fairfield CA
Cellulite Treatment
Cellulite is a skin condition commonly situated in the hips, thighs and buttocks. It has a cottage cheese appearance and multiple dimples on the skin. It is not related to being overweight but is genetic.
Cellulite treatment is not a surgical procedure. Treatment does not break the skin. It is a safe non-surgical approach to body contouring.
Best candidates are men and women who are in good health, have good skin tone and have realistic expectations. The results will produce an improvement in skin tone, the appearance of stretchmarks, and loose skin may be improved.
It is recommended to add diet and exercise to daily routine while undergoing cellulite treatments.
The cellulite treatment called Mesotherapy is considered very effective. The cellulite area develops increased blood flow and lymphatic flow, decreased fibrosis of the connective tissue and reduction of fat deposits. The result is smooth skin and cellulite reduction. This type of cellulite treatment uses a mixture of substances including vitamins, herbs and other homeopathic medications. This treatment is custom-tailored for each individual. Very short and thin needles re used to inject the formulations.
When treating cellulite, one formulation of medications may be used to dissolve fat, and another to destroy fibrous bands that bind the skin. This treatment is virtually painless. One can return to normal activities immediately.
The risks involved in this treatment are the possibility of allergic reaction to the mesotherapy solution. Since a needle is used, there is a possibility of infection at the site of injections. Mild or minor bruising at injection site is also a possibility. There may also be some itching after the treatment.
This procedure is performed in a medical setting. The patient does not need anesthesia. No post-operative recovery time. For those with sensitive skin, an anesthetic cream can be applied 1/2 hour before the treatment.
Another cellulite treatment is Lipodissolve. This is also a non-surgical procedure. This cellulite treatment involves the injection of phosphatidylcholine (PPC) into small fat deposits to dissolve fat. PPC is a natural enzyme. This compound is injected into the fat through multiple microinjections. The treatment is to dissolve fat which is removed through normal waste removal. It is virtually painless. No heavy bandages and one can resume work with no down time.
The procedure takes 30-60 minutes depending on areas treated. The patient can return to normal activities after the procedure.
The risks involved are the same as the above treatment. Plus the patient might feel light-headedness or slight nausea. This should pass quickly. The area treated will be swollen and tender for a few days and up to a few weeks.
SmartLipo, also known as laser liposuction is the latest fat removal treatment. This procedure involves the use of a laser that dissolves the fat and tightens the surrounding skin. This treatment is done in an office and does not require general anesthetic. The doctor will mark the targeted areas and local anesthetic is given. A small tube containing a laser is inserted into the skin. The laser's energy causes the fat cells to rupture and drain away. This is removed by the body's waste system. With this cellulite treatment, there is less bleeding and swelling. This causes the skin to tighten and shrink gradually in about 6-8 weeks.
The risks involved in this procedure are mild swelling, bruising or tenderness at site of insertion. There is rarely infection and a possibility of haematoma (collection of blood underneath the skin) following treatment. Asymmetrical results and minor scarring can be long term risks.
Best results are seen after 2 months. Downtime is minimal. The patient can return to work within 24 hours.
More Fairfield info...
Fairfield Sleep
Best Western Cordelia Inn, 4373 Central Place, ? +1 707 864-2029 (toll free: +1 800 422-7575, fax: +1 707 864-5834), [1].
Courtyard Fairfield Napa Valley Area, 1350 Holiday Lane, ? +1 707 422-4111 (fax: +1 707 428-3452), [2].
Fairfield Get out This article is an outline and needs more content. It has a template, but there is not enough information present. Please plunge forward and help it grow!
Plastic Surgery News...
- Abiomed Inc. (NASDAQ: ABMD) recently received a proposed National Coverage Decision (NCD) from the Centers for Medicare & Medicaid Services (CMS) for its AbioCor® Total Replacement Heart."This proposed decision is a positive development for the advancement of our AbioCor program in the United States," said Michael R. Minogue, Chairman, President and CEO of Abiomed.
Context Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST).
Objectives To compare 6 months of AST and radiation therapy (RT) to RT alone and to assess the interaction between level of comorbidity and all-cause mortality.
Design, Setting, and Patients At academic and community-based medical centers in Massachusetts, between December 1, 1995, and April 15, 2001, 206 men with localized but unfavorable-risk prostate cancer were randomized to receive RT alone or RT and AST combined. All-cause mortality estimates stratified by randomized treatment group and further stratified in a postrandomization analysis by the Adult Comorbidity Evaluation 27 comorbidity score were compared using a log-rank test.
Main Outcome Measure Time to all-cause mortality.
Results As of January 15, 2007, with a median follow-up of 7.6 (range, 0.5-11.0) years, 74 deaths have occurred. A significant increase in the risk of all-cause mortality (44 vs 30 deaths; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1-2.9; P = .01) was observed in men randomized to RT compared with RT and AST. However, the increased risk in all-cause mortality appeared to apply only to men randomized to RT with no or minimal comorbidity (31 vs 11 deaths; HR, 4.2; 95% CI, 2.1-8.5; P < .001). Among men with moderate or severe comorbidity, those randomized to RT alone vs RT and AST did not have an increased risk of all-cause mortality (13 vs 19 deaths; HR, 0.54; 95% CI, 0.27-1.10; P = .08).
Conclusions The addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable-risk prostate cancer. This result may pertain only to men without moderate or severe comorbidity, but this requires further assessment in a clinical trial specifically designed to assess this interaction.
Trial Registration clinicaltrials.gov Identifier: NCT00116220